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Firstly, parathyroid hormone (1-14) [PTH (1-14)] analogue
containing various -amino-iso-butyric acid residue (Aib)α
was synthesized by exchanging the 1st and 3rd Ala residues
of alpha carbon of PTH (1-14). This analogue revealed to
have the quite tight and stable -helical structure using theα
nuclear magnetic resonance (NMR) analysis. The biological
activities of these analogues were examined using a cAMP-
generating assay in LLC-PK1 cell lines stably transfected
with the wild- type human PTH1 receptor. Only the PTH
analogue substituted with methyl moiety without acetylation
showed significant cAMP generating action with 15.0 ±
3.414 of EC50. Then, we used an ovariectomized rat model
system to compare the in vivo effects of parathyroid hor-
mone analogue with that of PTH (1-84). Daily subcutaneous
administration of the unacetylated Aib1,3PTH (1-14) for 5
weeks in 30 nM/kg subcutaneously with positive control
group receiving PTH (1-84) with 8 nM/ kg were performed.
However, there was no significant change in spinal or
femoral bone mineral density assessed by dual x-ray absorp-
tiometry (DXA) in the Aib1,3PTH (1-14) group where defi-
nite increase of these parameters shown in the PTH (1-84)
group (p < 0.001). Assessment of bone strength was eval-
uated with no significant differences among all groups. It
was quite disappointing to see the actual discrepancies
between the result of significant pharmacokinetic potency
and the in vivo clinical effect of the Aib1,3PTH (1-14).
However, there are several limitations to mention, such as
the short duration of treatment, matter of dosage, and
insufficient effect of tight -helical structures with absenceα
of C-terminus. In conclusion, our findings suggest that
unacetylated Aib1,3PTH (1-14) did not exhibit any anabolic
effects at the bones of ovariectomized rats.
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INTRODUCTION
Osteoporosis is a disease characterized by dete-
riorated bone strength which will finally lead to
increased bone fragility and consequent increased
risk of fractures.1 Current available therapy for the
treatment of osteoporosis is based on inhibition of
bone resorption to prevent further bone loss. As
there is substantial limitation of these anti-resorp-
tives based on that there is already significant loss
of bone, need for drugs that will stimulate bone
formation existed. Low dose, intermittently ad-
ministered parathyroid hormone (PTH) has re-
cently approved by Food and Drug Administra-
tion (FDA) in year 2002. PTH causes a significant
increase in bone mass in animals and humans,
improves mechanical strength, and preserves
trabecular bone connectivity in an animal model
of osteoporosis.
2-7
However, there is still a practi-
cal problem regarding mode of administration.
Only injection is available since the long peptide
is degraded in the intestine.
The osteoblasts are the primary target cells for
the anabolic effects of PTH on bone tissue. Bind-
ing of PTH to the seven-membrane spanning
G-protein-coupled receptor and activation of both
the 3,5-cyclic adenosine monophosphate (cAMP)-
dependent protein kinase A (PKA) pathway and
the phospholipase C-dependent protein kinase C
pathway are the main signal streams to stimulate
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the osteoblasts.8 The mechanisms of the anabolic
action of PTH are still not completely under-
stood. However, referring to the previous in vivo
studies using the N-terminal-truncated PTH frag-
ment, which lacks PKA activity stimulation of
cAMP production, failed to show the anabolic
effect of PTH.8-10 This indicates that this particular
region with the subsequently activated cAMP
pathway is the critical portion in the anabolic
effect of PTH. Therefore using shorter PTH an-
alogue contating critical portion will be useful in
both aspect of the effect and possible convenient
oral administration.
The amino-terminal portion is critical for PTH
and PTH-related peptide (PTH/PTHrp) receptor
activation.11,12 N-terminus of PTH (1-14) weakly
stimulated cAMP formation, about 10-3 folds of
PTH (1-34) in LLC-PK cells stably expressing a
high level of the hPTH/PTHrp receptor.13 Sub-
stituted PTH analogues of each residue were
analyzed subsequently. The short amino-terminal
peptides of PTH, with various residues changed,
could possibly be optimized to significantly in-
crease signaling potency by modifying the interac-
tions involving receptor regions containing the
trans-membrane domains and the extra-cellular
loops.14,15 PTH (1-14) is regarded as the basic
entity required for receptor activation, but the
functionality of PTH (1-14) required for PTH/
PTHrp receptor activation is retained in the first
9 amino acids.15
The previous extensive study on the structural
and functional study on the various forms of PTH
analogue was done. PTH (1-12) or PTH (1-11) with
variable amino acid changes lead the different -α
helical structure with significant effect on cAMP
production level.16 As the side chain and the alpha-
helical structure seemed important, the newly
formulated PTH analogue was composed of N-
terminal 14 amino acid with especially substituted
1st amino acid to the moiety containing the -α
amino-iso-butyric acid residue (Aib)1,3 form from
alanine residue. To confirm whether this specifi-
cally modified analogue, Aib1,3 PTH (1-14), was
effective in vitro and in vivo, this agent was tested
on the production of cAMP and administered in
the ovariectomized rat model analyzing the bone
density and bone strength.
MATERIALS AND METHODS
Materials-peptide synthesis
The peptides used in this study were syn-
thesized at Korea Basic Science Institute (Seoul,
Korea) using the solid phase approach and they
were purified by high performance liquid chro-
matography (HPLC). Peptide sequences were
assembled with Milligen 9050 (Fmoc Chemistry).
For deprotection, reagent mixture (88% trifluoro-
acetic acid, 5% phenol, 2% triisopropylsilane, 5%
H2O; 2 h) was used. The raw peptides were
purified by HPLC (Delta PAK 15 C18 300Å 3.9μ
× 150 mm column), with a 240 nm detector. Mass
spectroscopy was used to confirm the molecular
masses of the synthesized peptides.
cAMP generating assay
PTH receptor was stably expressed in the LLC-
PK1 porcine kidney cells as previously de-
scribed.16 LLC-PK1 cells expressing the receptors
were grown to confluence in 48-well plates. Cell
culture medium was changed to complete Medi-
um-199 containing 3% FBS 3-4 hrs before the
cells were treated with peptides. For the assays,
the medium was first removed and the cells
were washed with 0.25 mL of cAMP-generating
medium containing 3% FBS, 2 mM 3-isobutyl-1-
methyl-xanthine, 0.1% BSA, 20 mM HEPES, and
0.002% ascorbic acid in complete Medium-199.
cAMP-generating media (0.15 mL) containing
various concentrations of peptides were added
and the cells were incubated for 30 mins at 37 .
The media was then completely discarded, and
the cells frozen at -70 for 30 min and thawed
at room temperature for 15-20 min; this freeze-
thawing process was repeated twice. The cells
were then detached from the plates with 0.5 mL
of 50 mM HCl solution per well, transferred to a
1.5 mL Eppendorf tube and centrifuged at 1900 ×
g for 10 min. The supernatants were then
diluted 50-fold with radio-immunoassay (RIA)
buffer and the cAMP concentration was mea-
sured using a cAMP 125I RIA Kit (Stoughton,
MA, USA), according to the manufacturer's in-
structions. The mean values of the data were
fitted to a sigmoid curve with a variable slope
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factor using the nonlinear squares regression
technique in the GRAPHPAD PRISM. EC50 (nM)
values are represented by means ± SE. All of the
cAMP assays were performed in triplicate wells
and repeated twice. (p<0.05 was considered
significant).
NMR spectroscopy and modeling calculations
All NMR experiments are carried out in 70%
H2O (D2O)/30% 2,2,2-trifluoro-(d3)-ethanol (TFE)
and 90%H2O/10% D2O at pH 7.2. The concentra-
tion was 1.5 mM in 50mM phosphate buffer. NMR
spectra were acquired at 288K on a Bruker DRX-
500 spectrometer (Rheinstetten, Germany) equipped
with a triple resonance probe, and triple axis
gradient coils. The spectra were also recorded
over the temperature range 10-25 , to calculate
the temperature coefficients. Pulsed-field gradient
(PFG) techniques were used in all H2O experi-
ments to suppress solvent signals. Two-dimen-
sional total correlation spectroscopy (TOCSY),17
with an MLEV-17 mixing pulse of 69.7 ms, and
twodimensional (2-D) nuclear overhauser effect
spectroscopy (NOESY),18 with mixing times of
100-600 ms, was also performed. Two-dimensional
double-quantum-filtered correlated spectroscopy
(DQF-COSY)19 spectra were collected in H2O to
obtain the vicinal coupling constants. NMR data
were processed using XWIN-NMR (Bruker Instru-
ments) software, and the processed data further
analysed using sparky 3.60 software. Starting
structures were generated using distance geo-
metry (DG) by employing a refinement protocol
using distance restraints assigned as strong,
medium, or weak, on the basis of cross-peak
volumes in the NOESY spectra. The dihedral
angle constraints were also deduced from the
3
JHN
α coupling constants from the 2-D DQF- COSY
spectra in H2O. Structure calculations were per-
formed using hybrid distance geometry and the
dynamically simulated-annealing (SA) protocol20-23
using the CNS ver. 2.0.24
Animals and treatment
Thirty-six, five-month-old, virgin female Spra-
gue-Dawley rats were purchased from the Depart-
ment of Laboratory Animal Medicine at Yonsei
Medical Research Center (Seoul, Korea). They
were housed in a room maintained at 22.2 with
12-h light and 12-h dark cycles. The animals were
fed freely with Purina laboratory rodent chow
(Hagribrand Purina Korea Co., Kunsan, Korea),
which contained 1.17% calcium, 0.77% phosphor-
ous and 2.6 IU vitamin D per gram. All animals
were treated in accordance with the guidelines
and regulations for the use and care of animals of
Yonsei University, Seoul, Korea.
Experimental design
The animals were randomized into the fol-
lowing four groups at the age of 9 weeks, with
seven rats per group, and four rats were housed
per cage. They were all ovariectomized (ovx) at
the age of 10 weeks except the sham group. All
the rats were left without any treatment for fur-
ther 4 weeks. The first sham group and ovx group
were treated with a vehicle (0.9% normal saline)
for 5 weeks from the age of 14 week. All the rats
in the remaining 2 groups were treated subcu-
taneously with recombinant human PTH (1-84)
(rhPTH (1-84), 8 nM/kg) and Aib1,3PTH (1-14) (30
nM/kg) for 5 weeks, respectively. The rhPTH
(1-84), kindly donated by the Mogam Biotechno-
logy Research Institute (Kyungi, Korea), was dis-
solved in 0.9% normal saline. Aib1,3PTH (1-14) was
also dissolved in 0.9% normal saline. At the end
of the 5 weeks of treatment, the rats were sacri-
ficed, and the femur and vertebrae were harvested
and stored in saline-soaked gauze at -20 until
required for analysis.
Bone densitometry
The bone mineral density (BMD) of the excised
lumbar spine and right femora was measured by
dual energy X-ray absorptiometry (DXA) (QDR-
4500A, Hologic, Waltham, MA, USA). The specific
bone was scanned at a resolution of 0.5 mm with
a scanning speed of 2 mm/sec. The region was
analyzed for bone mineral content (BMC), pro-
jected bone area and BMD. The triplicate deter-
minations of the five different femora, with
repositioning, showed a coefficient of the varia-
tion at 0.59%.
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Femoral length and cross-sectional diameter at
mid-diaphysis
The left femur lengths were measured using a
Mitutoyo digital caliper (Cole Parmer, Vernon
Hills, IL, USA). The femoral length was measured
from the greater trochanter to intercondylar fossa.
The length at the anterior-posterior (AP) and
medial-lateral (ML) positions were measured.
Mechanical testing
The femurs were thawed prior to testing, and
the bone strength of the intact femurs was
measured using a three-point bending test. A load
was applied midway between two supports that
were 15 mm apart. The femurs were positioned so
the loading point was 7.5 mm proximal from the
distal popliteal space, and bending occurred about
the medial-lateral axis. Load-displacement curves
were recorded at a crosshead speed of 1 mm/sec
using a servo-hydraulic materials testing machine
(Instron LTD, Buckinghamshire, England) and an
X-ray recorder (Hewlett Packard 7090A, Palo Alto,
CA, USA).
Statistical analysis
All data were expressed as the means and
standard deviation. SPSS 10.0 software (Chicago,
Illinois, USA) was used for the statistical analysis.
The differences in the BMD, cortical diameter and
length, and various biomechanical data between
the groups were compared using ANOVA with a
Bonferroni's multiple group comparison pro-
cedure. A p value of less than 0.05 was accepted
as statistically significant.
RESULTS
Schematic structures of PTH analogues
Basic chemical structure of PTH (1-14) in the 1
st
and 3rd Ala residues of alpha carbon is shown in
Fig. 1A. These two sites were substituted with
various moieties such as methyl, ethyl or propyl
moieties (Fig. 1B).
Biological effect of substitution in the 1st, 7th and
8th residues in vitro
Substitution of Ala1 by methyl moiety sub-
stituted with ethyl or propyl moiety in Ala1
showed no activity in cAMP generation (Fig. 2A).
However, substitution of Ala1 by methyl moiety
with unacetylation preserved cAMP production;
however, acetylation of this analogue remarkably
reduced cAMP accumulation (Fig. 2B).
Resonance assignment and NMR solution struc-
ture
To examine structure-function relationship of
N-terminal acetylation of PTH (1-14), we deter-
mined solution structure of the Aib1,3PTH (1-14).
All resonance assignments of proton were pos-
sible using the standard sequential resonance as-
signment procedure.25 As Aib moiety has no
amide proton, it was assigned indirectly using
NOESY spectra. As a consequence of NOE as-
signment and structure calculation, Aib
1,3
PTH
(1-14) shows a tight -helical structure. A numberα
of continuous stretch of intense dNN(i,i+1) NOEs
are detected (Fig. 3). There are other short range
dNN NOEs, supporting its helical structure (data
not shown). To confirm the helical structure of
Aib
1,3
PTH (1-14), we displayed summary of the
Fig. 1. Schematic structures of PTH analogs.
A
B
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NMR data in aqueous 30% TFE condition (Fig. 4).
The d Nα (i,i+1) as well as dαβ (i,i+3) and d Nα (i,i+1)
NOEs also support -helical structure of Aibα 1,3
PTH (1-14), especially residues from Glu
4
to Ala
10
.
The NMR structure was calculated using the
experimental restraints derived from 2D-NOESY
and DQF-COSY spectra. The 50 DG structures
served as starting structures for dynamical simu-
lated-annealing calculation. None of the 50 struc-
tures showed restraint violations > 0.05 nm for
distances and 5 for torsion angles. The 15 lowest
energy structures (<SA>k) were selected from the
50 simulated-annealing structures for further struc-
tural analysis. The average structure (<SA>k) was
calculated from the geometrical average from 15
<SA>k structure coordinates and was subjected to
restraint energy minimization (REM) to correct
covalent bonds and angle distortions. Final 15
structures, superimposed upon the energy-mini-
mized average structure and ribbon diagram REM
structure are displayed (Fig. 5). The main -helicalα
region, Glu4 to Ala10 is compatible with NOEs and
other NMR derived data. Considering the features
of secondary structure, we can conclude that
acetylation of the amino terminus does not make
a critical effect on secondary structure of PTH
(1-14) peptide. This conclusion is also consistent
with the result that activities of cAMP formation
of native PTH (1-14) and Aib1,3PTH (1-14) have no
significant differences.
Fig. 2. cAMP formation of various PTH analogues in LLC-PK1 cells stably transfected with hPTH1R. (A) The effect
of 1
st
and 3
rd
residue substitution in PTH (1-14) with methyl, ethyl and propyl moiety on cAMP activity. (B) The effects
of acetylation in the AiBPTH (1-14) analogue. Each experiment was performed in duplicate and repeated three times.
The symbols are defined in the figure key, and the curves were fitted to the data points by non-linear regression
analysis, as described in Materials AND Methods.
Fig. 3. Two-dimensional NOESY spectrum of modifica-
tions of PTH (1-14) showing NH regions with a mixing
time 400 ms. Modification PTH (1-14) dissolved in 30%
TFE solution at pH 7.2, 288 K. A continuous stretch of
sequential dNN (i, i+1) NOEs is observed in the helical
region.
Fig. 4. Summary of NMR data for modifications of PTH
(1-14) collected in 30% TFE solution at 288 K, showing
the sequential and short-range NOE contacts. Slowly ex-
changing amide protons ( ), backbone vicinal coupling
constants ( ;
3
JHN(<6 Hz), and chemical shift indices
(CSI) for the C Hα chemical shift are indicated.
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Skeletal effect of PTH analogue in vivo
After five weeks of injection, the excised lum-
bar spine (L1-L5) and right femur were an-
alyzed by DXA. The BMC and BMD of the
right femora were 7.2 and 5.2% lower and those
of the lumbar spine were 3.0 and 7.6% lower in
the ovx group respectively, than in the SHAM
group (p<0.05) (Fig. 6A, 6B). Treatment of the
ovx rats with rhPTH (1-84) for 5 weeks, re-
sulted in a greater femoral and spinal BMD
than in the ovx group (10.9% & 12.9%, respec-
tively, p<0.001) In contrast, the rats adminis-
tered with Aib1,3PTH (1-14) showed no signifi-
cant changes in BMD in both regions compared
to ovx rats.
The femoral lengths after five weeks showed
that in the groups treated with PTH (1-84) only
showed significantly increased length (p<0.05)
(Table 1).The femora diaphyses were evaluated
with the three-point bending test at mid-shaft
(Table 1). However, interestingly, there were no
significant differences among all the groups
treated nor untreated on the parameters such as,
ultimate force (Fu), stiffness (S), ultimate stress
(σu), Young's modulus (E) and toughness(u).
Fig. 6. Bone mineral density (BMD, g/cm2) of the right
femur (A). *p<0.05 vs. PTH14, **p<0.001 vs. OVX, PTH
14; lumbar spinal BMD (B); *p<0.005 vs. OVX, PTH14,
**p<0.001 vs. OVX, PTH14.
Table 1. Anthropometric and Biomechanical Parameters of the Femora
Length (mm) AP (mm) ML (mm) Fu (N) εu (mm) U (N/mm
2)
SHAM 35.9/0.94 3.4/0.3 4.0/0.09 141.2/12.4 0.88/0.18 0.06/0.02
OVX 36.6/0.58 3.4/0.14 4.1/0.14 152.3/20.5 0.81/0.19 0.06/0.02
PTH84 37.5/ 0.58* 3.4/0.20 4.0/0.12 149.3/8.4 0.79/0.19 0.06/0.02
PTH14 36.6/0.62 3.5/0.13 3.8/0.25 137.5/5.8 0.72/0.16 0.05/0.02
Data are shown as the mean ± SD.
The whole femoral length and the diameters of anterior-posterior and medio-lateral part of the mid-diaphysis are denoted in mm.
The cortical bones of the femora diaphysis were examined using the three-point bending test to measure the ultimate force (Fu),
ultimate strain ( u) and modulus of toughness (u).ε
*p<0.05 vs. OVX.
Fig. 5. Solution structures of Aib
1,3
PTH (1-14). (A) Super-
imposition of the final 15 <SA>k structures of PTH (1-14)
analogue upon the energy-minimized average structure
(<SA>k) (C
α
traces) (B) Ribbon diagram of the PTH (1-14)
analogue. Modified Aib
1
, Aib
3
, Nle
8
residues are dis-
played using ball and stick model.
A
B
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DISCUSSION
As the Aib residues are known to have a strong
tendency to form type III -bends, 310-helix inβ -
creasing helicity, the Aib containing PTH (1-14)
were synthesized around critical positions of 1st
and 3rd positions of N-terminus.26,27 The results of
the conformational studies presented in this work
show that the solution structure of unacetylated
Aib1,3 substituted PTH (1-14) analogues in the
solvent system is characterized by tight helical
segments. It was found that insertion of Aib resi-
dues at positions 1, 3 increased helicity in all
tested peptides with consequent enhancement of
potency and binding affinity.
Previous reports on the effect of shortened and
modified PTH analogues in vivo have shown some
of the significant effect compared to the FDA
approved PTH (1-34). A lactam derivative of PTH
(1-31)NH2 itself also stimulates trabecular growth
in the distal femurs of ovx rats as strongly as
hPTH (1-34) only when injected at a high daily
dose but it was only about 70% as effective as
hPTH (1-34) when injected suboptimally.28 Another
report demonstrated that: PTH (1-31) was as
potent as PTH (1-34) on the bone formation in
mice but were less potent in stimulating bone
resorption parameters in mice.29 In addition there
was difference degrees of increasing bone for-
mation according to the site such as periosteal or
endosteal region.29 Therefore, these results in-
dicate that the modified PTH analogues with
similar biological potency might show quite dif-
ferent skeletal effect when administered in vivo
system.
Data on the shorter PTH analogues are mainly
on the in vitro biological potency and the structu-
ral-based analysis. For example, none of the 6/10
substituted analogues with linear or cyclic form
remained as active as the parent peptide but the
lactam-bridged analogues either maintained po-
tency or showed 6-fold improvement.30,31 There-
fore, it is thought that an -helical conformaα tion
of the N-terminal fragment of PTH and the
structural order of the very first residues (1-4) of
the signaling domain seemed critical in PTH
action. NMR analysis on the unacetylated Aib1,3
PTH (1-14) showed quite effective -helical strucα -
ture which was re-confirmed in the cAMP gene-
rating assay. However, contrary to the expec-
tations usual acetylation of the peptide remark-
ably reduced the biological activity of the Aib1,3
PTH (1-14). Thereafter, only the unacetylated
Aib1,3 PTH (1-14) was used in the following in vivo
evaluation.
There were no significant changes in BMD or
bone strength. The null effect of unacetylated
Aib1,3 PTH (1-14) in the ovx rat model was quite
disappointing. However, these results indicate
several important aspects of the modified short
analogues of PTH. Firstly, the absence of C-ter-
minus of the PTH which is thought to be quite
important part in the effective signal transduction
through the PTH receptor, might have signifi-
cantly affected the anabolic effect even though
there was good binding response of Aib1,3 PTH
(1-14) with the PTH receptor. The presence of the
ordered two helical segments in the N-terminal
and C-terminal is assumed to be essential for
bioactivity. It means that the both of the activation
and binding domains are important.32 Secondly,
our previous report and the recent reports by
others, the -helical structure of the PTH anα -
alogues are thought to be important in deter-
mining the activity by residue specificity in terms
of optimum receptor pocket binding and helix
stability.16,31 However, it seems that only the tight
and stable -helical structure does not explain theα
whole biological effect of the modified analogues.
Thirdly, the lysine and arginine residues of this
Aib1,3 PTH (1-14) might be the reason of null effect
in that these residues are responsible for the
peptide degradation, therefore, the action time of
the Aib1,3 PTH (1-14) could have been too short to
show any effect with only once daily subcutane-
ous injection for 5 weeks. Lastly, the duration and
the dosage of the Aib1,3 PTH (1-14) might have
been far short to show enough anabolic effect as
was the case in the PTH (1-31)NH2 in suboptimal
dosage.28
In conclusion, the results of this study will as-
sist in the understanding of the structure-biologi-
cal activity relationships of short amino terminal
oligopeptides, and this will provide a future direc-
tion for the development of effective low mo-
lecular weight PTH analogues. The proper direc-
tion of new substitution and cyclized analogues of
PTH will lead to both for greater in vitro activity
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and possibly for improved delivery and greater
specificity as agents for restoration of bone loss in
osteoporosis.
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